Genes (Apr 2024)

Spectrum of <i>ERCC6</i>-Related Cockayne Syndrome (Type B): From Mild to Severe Forms

  • Jacopo Sartorelli,
  • Lorena Travaglini,
  • Marina Macchiaiolo,
  • Giacomo Garone,
  • Michaela Veronika Gonfiantini,
  • Davide Vecchio,
  • Lorenzo Sinibaldi,
  • Flaminia Frascarelli,
  • Viola Ceccatelli,
  • Sara Petrillo,
  • Fiorella Piemonte,
  • Gabriele Piccolo,
  • Antonio Novelli,
  • Daniela Longo,
  • Stefano Pro,
  • Adele D’Amico,
  • Enrico Silvio Bertini,
  • Francesco Nicita

DOI
https://doi.org/10.3390/genes15040508
Journal volume & issue
Vol. 15, no. 4
p. 508

Abstract

Read online

(1) Background: Cockayne syndrome (CS) is an ultra-rare multisystem disorder, classically subdivided into three forms and characterized by a clinical spectrum without a clear genotype-phenotype correlation for both the two causative genes ERCC6 (CS type B) and ERCC8 (CS type A). We assessed this, presenting a series of patients with genetically confirmed CSB. (2) Materials and Methods: We retrospectively collected demographic, clinical, genetic, neuroimaging, and serum neurofilament light-chain (sNFL) data about CSB patients; diagnostic and severity scores were also determined. (3) Results: Data of eight ERCC6/CSB patients are presented. Four patients had CS I, three patients CS II, and one patient CS III. Various degrees of ataxia and spasticity were cardinal neurologic features, with variably combined systemic characteristics. Mean age at diagnosis was lower in the type II form, in which classic CS signs were more evident. Interestingly, sNFL determination appeared to reflect clinical classification. Two novel premature stop codon and one novel missense variants were identified. All CS I subjects harbored the p.Arg735Ter variant; the milder CS III subject carried the p.Leu764Ser missense change. (4) Conclusion: Our work confirms clinical variability also in the ERCC6/CSB type, where manifestations may range from severe involvement with prenatal or neonatal onset to normal psychomotor development followed by progressive ataxia. We propose, for the first time in CS, sNFL as a useful peripheral biomarker, with increased levels compared to currently available reference values and with the potential ability to reflect disease severity.

Keywords